[go: up one dir, main page]

BR9508053A - Construction of recombinant yeast strain vector DNA expression and process for the production of a heterologous protein - Google Patents

Construction of recombinant yeast strain vector DNA expression and process for the production of a heterologous protein

Info

Publication number
BR9508053A
BR9508053A BR9508053A BR9508053A BR9508053A BR 9508053 A BR9508053 A BR 9508053A BR 9508053 A BR9508053 A BR 9508053A BR 9508053 A BR9508053 A BR 9508053A BR 9508053 A BR9508053 A BR 9508053A
Authority
BR
Brazil
Prior art keywords
construction
production
heterologous protein
yeast strain
vector dna
Prior art date
Application number
BR9508053A
Other languages
Portuguese (pt)
Inventor
Thomas Borglum Kjeldsen
Knud Vad
Jokob Brandt
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9508053A publication Critical patent/BR9508053A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9508053A 1994-06-17 1995-06-16 Construction of recombinant yeast strain vector DNA expression and process for the production of a heterologous protein BR9508053A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK71294 1994-06-17
PCT/DK1995/000250 WO1995035384A1 (en) 1994-06-17 1995-06-16 N-terminally extended proteins expressed in yeast

Publications (1)

Publication Number Publication Date
BR9508053A true BR9508053A (en) 1997-08-12

Family

ID=8096676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508053A BR9508053A (en) 1994-06-17 1995-06-16 Construction of recombinant yeast strain vector DNA expression and process for the production of a heterologous protein

Country Status (16)

Country Link
EP (1) EP0765395A1 (en)
JP (1) JP3730255B2 (en)
CN (1) CN1131312C (en)
AU (1) AU2733595A (en)
BR (1) BR9508053A (en)
CA (1) CA2192943A1 (en)
CZ (1) CZ363796A3 (en)
FI (1) FI965030A7 (en)
HU (1) HUT75840A (en)
IL (1) IL114160A (en)
MX (1) MX9606536A (en)
NO (1) NO965411L (en)
PL (1) PL317761A1 (en)
SG (1) SG47883A1 (en)
WO (1) WO1995035384A1 (en)
ZA (1) ZA954983B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6017731A (en) 1996-12-13 2000-01-25 Chiron Corporation Method for expression of heterologous proteins in yeast
ATE317443T1 (en) * 1996-12-20 2006-02-15 Novo Nordisk As N-TERMINAL EXTENDED PROTEINS EXPRESSED IN YEAST
EP1049790A1 (en) * 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
DE60044728D1 (en) 1999-12-29 2010-09-02 Novo Nordisk As METHOD FOR THE PRODUCTION OF INSULIN FORECASTS AND ANALOGS OF INSULIN PROCESSORS WITH IMPROVED FERMENTATION EXPORTS IN YEAST
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
EP1421102A2 (en) * 2001-07-24 2004-05-26 Novo Nordisk A/S Method for making acylated polypeptides
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
CN1902226A (en) 2003-12-03 2007-01-24 诺和诺德公司 Single-chain insulin
ATE513921T1 (en) 2005-08-16 2011-07-15 Novo Nordisk As METHOD FOR PRODUCING MATURE INSULIN POLYPEPTIDES
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
BRPI0717098B8 (en) 2006-09-22 2021-05-25 Novo Nordisk As protease-resistant human insulin analogues, pharmaceutical composition and process for their preparation
EP2069502B1 (en) 2006-09-27 2014-02-26 Novo Nordisk A/S Method for making maturated insulin polypeptides
WO2008062010A2 (en) 2006-11-22 2008-05-29 Novo Nordisk A/S Method for making activated carboxypeptidases
CN101743252A (en) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 protease stabilized, pegylated insulin analogues
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
CN101784562B (en) 2007-08-15 2016-07-13 诺沃-诺迪斯克有限公司 There is the insulin analog of acyl group and aklylene glycol moiety
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
PT2254906T (en) 2008-03-18 2017-01-03 Novo Nordisk As Protease stabilized, acylated insulin analogues
CN102065903B (en) 2008-04-01 2015-02-18 诺沃-诺迪斯克有限公司 Insulin albumin conjugates
RU2533217C3 (en) 2009-06-26 2020-12-21 Ново Нордиск А/С PREPARATION CONTAINING INSULIN, NICOTINAMIDE AND AMINO ACID
CN102639559B (en) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 Methods for preparing polypeptides
BR112012033107A2 (en) 2010-06-23 2016-10-11 Novo Nordisk As insulin derivatives containing additional disulfide bonds.
US8883722B2 (en) 2010-06-23 2014-11-11 Novo Nordisk A/S Human insulin containing additional disulfide bonds
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
EP2651446A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US20130331320A1 (en) 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
JP6058646B2 (en) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス Multi-substituted insulin
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
JP6735561B2 (en) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs
EP3004156A1 (en) 2013-06-07 2016-04-13 Novo Nordisk A/S Method for making mature insulin polypeptides
CN120060321A (en) 2014-02-28 2025-05-30 诺和诺德股份有限公司 Mating factor alpha propeptide variant
JP6983075B2 (en) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス Insulin with polar recombination extension
BR112018002416A2 (en) 2015-08-25 2018-09-18 Novo Nordisk As insulin derivatives and their medical uses
JP2018531899A (en) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス Novel insulin derivatives and their medical use
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
AU2017269496B2 (en) * 2016-05-24 2021-03-25 Novo Nordisk A/S MIC-1 compounds and use thereof
JP2020531451A (en) 2017-08-17 2020-11-05 ノヴォ ノルディスク アー／エス New acylated insulin analogs and their use
US20210230659A1 (en) * 2018-06-18 2021-07-29 Unichem Laboratories Ltd Leader Sequence for Higher Expression of Recombinant Proteins
CN110305223B (en) * 2019-06-26 2022-05-13 重庆派金生物科技有限公司 Method for preparing target polypeptide by recombinant tandem fusion protein
FI4073097T3 (en) 2019-12-11 2024-08-13 Novo Nordisk As NEW INSULIN ANALOGUES AND THEIR METHODS OF USE
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593518B1 (en) * 1985-05-02 1989-09-08 Transgene Sa VECTORS FOR THE EXPRESSION AND SECRETION OF HIRUDIN BY TRANSFORMED YEASTS
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
DK105489D0 (en) * 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
DK300090D0 (en) * 1990-12-19 1990-12-19 Novo Nordisk As PROCEDURE FOR PREPARING LEADER SEQUENCES
WO1992013951A1 (en) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells

Also Published As

Publication number Publication date
CZ363796A3 (en) 1997-05-14
IL114160A (en) 2006-12-31
FI965030L (en) 1997-02-14
CN1131312C (en) 2003-12-17
FI965030A7 (en) 1997-02-14
CA2192943A1 (en) 1995-12-28
HUT75840A (en) 1997-05-28
HU9603476D0 (en) 1997-02-28
MX9606536A (en) 1997-03-29
JPH10501695A (en) 1998-02-17
JP3730255B2 (en) 2005-12-21
FI965030A0 (en) 1996-12-16
NO965411D0 (en) 1996-12-16
ZA954983B (en) 1996-02-14
AU2733595A (en) 1996-01-15
EP0765395A1 (en) 1997-04-02
SG47883A1 (en) 1998-04-17
IL114160A0 (en) 1995-10-31
PL317761A1 (en) 1997-04-28
NO965411L (en) 1997-02-14
CN1152942A (en) 1997-06-25
WO1995035384A1 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
BR9508053A (en) Construction of recombinant yeast strain vector DNA expression and process for the production of a heterologous protein
BR8202422A (en) BACILLUS CLONING VECTOR PROCESS FOR ITS BUILDING RECOMBINANT DNA MOLECULE PROCESS FOR ITS CONSTRUCTION AND PROCESS FOR THE PRODUCTION OF A POLYPEPTIDE
BRPI9801092B8 (en) process for the production of recombinant factor viii and cell culture medium.
DE69611102D1 (en) STRENGTHENING THE MUTAGENESIS OF NUCLEIC ACIDS
FI950628L (en) Modified fungal cells and method for producing recombinant products
BR9403442A (en) Silanes, process for their production and application of said silanes
DE69427603D1 (en) Multi-processor method for the disassembly of ATM packets
EE9700137A (en) Aerosol forms of peptides and proteins
BR9601256A (en) Process for the fragmentation of ore material
FI960331L (en) Transformation systems of the yeast Gandida utilis and the expression of foreign genes using them
NO971875D0 (en) Cathepsin 02 protease
FI965032L (en) Interleukin-5-specific recombinant antibodies
FI962247L (en) Novel apoptosis-modifying proteins, the DNA encoding them, and methods of using them
BR9101137A (en) METHOD FOR THE PREPARATION OF A HYBRID VECTOR, PROCESS FOR THE PREPARATION OF A DNA MOLECULE, METHOD FOR THE PREPARATION OF A HOST AND FOR THE PREPARATION OF A POLYPEPTIDE AND METHOD FOR THE PREPARATION OF PURE PSM
FI962693L (en) Gene expression control
FI961238A7 (en) Secretion sequence for heterologous protein production in yeast
EE200000152A (en) Amino-terminally truncated forms of MCP-2, DNA molecules, expression vector, host cell, recombinant protein production method, use of protein and pharmaceutical composition
BR9508714A (en) Compound process for preparing streptograms by muta-synthesis nucleotide sequence recombinant DNA vector use of a mutant strain sequence and / or polypeptide vector and pharmaceutical composition
PT789767E (en) PROCESS FOR THE PRODUCTION OF PURIFIED PAPILOMAVIRUS PROTEINS
BR9606270A (en) Process for the production of recombinant human beta-cis interferon protein and recombinant human beta-cis interferon protein
FI971100L (en) Method for producing recombinant DNA proteins, plasmids and modified cells
BR9709721A (en) Purified and isolated polynucleotide in a host cell vector process to produce chitanase humama to treat a fungal infection and to reduce the amount of a non-chitanase antifungal chitanase polypeptide fragment in a monoclonal antibody hiridoma cell line and pharmaceutical composition
EP1028095A4 (en) Reinforcing material, method of production thereof, reinforcing/repairing method using the reinforcing material, reinforcing/repairing structure, and structural element
AU5635896A (en) Recombinant endotoxin-neutralizing proteins
DE59712554D1 (en) RECOMBINANT EXPRESSION OF S-LAYER PROTEINS

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law